In the primary prevention of variceal hemorrhage, beta-blockers continue to be the first-line treatment. Newer nonselective beta-blockers with anti-alpha 1 -adrenergic activity, such as carvedilol, appear to have a better impact on reducing the hepatic venous pressure gradient than propranolol. The addition of isosorbide mononitrate appears to improve the effectiveness of beta-blockers in primary prophylaxis, but not that of somatostatin in the treatment of acute variceal hemorrhage. The use of vasoactive drugs alone in acute variceal bleeding has not proved to be more effective than endoscopic treatment. The advent of endoscopic variceal ligation (EVL) has strengthened the role of endoscopy in the management of bleeding esophageal varices. EVL has improved the results, particularly in terms of lowering the treatment-related morbidity, compared with endoscopic variceal sclerotherapy (EVS). However, the variceal recurrence rate after initial eradication with EVL is relatively high. In contrast to synchronous combined therapy with EVL plus EVS, metachronous combination of EVL and low-dose EVS may improve the results of EVL alone. For bleeding fundic varices, obliteration using cyanoacrylate is currently the treatment of choice. Endosonography (EUS) is coming into more widespread use in the assessment of variceal eradication and in further attempts to improve the results of endoscopic injection therapy. According to two metaanalysis studies, transjugular intrahepatic portosystemic shunt (TIPS) is not yet capable of replacing endoscopic treatment in the secondary prevention of variceal bleeding.
Introduction
Variceal bleeding and portal hypertension are still a therapeutic challenge. Despite the wide range of treatment modalities currently available, the mortality from first variceal hemorrhage and the rate of recurrent variceal bleeding remain high. There is still no generally accepted solution to the manifold problems associated with the management of acute variceal bleeding. Another issue concerns the eradication of large fundic varices. Is there any point in attempting primary prophylaxis against hemorrhage, and if so, how should one go about achieving it? Which method has the longest-lasting impact on the prevention of secondary variceal bleeding? Is transjugular intrahepatic portosystemic shunt (TIPS) ready to replace endoscopic treatment? What is the place for pharmacological therapy in the management of varices? Is there a role for endoscopic ultrasonography (EUS) in further improving the results of endoscopic treatment? The following review of current publications between June 1999 and August 2000 will attempt to pinpoint new insights into the management of esophagogastric varices.
Measuring Portal Pressure
Several studies have shown that effective prevention of first variceal bleeding can only be achieved if the hepatic venous pressure gradient (HVPG) is decreased to 12 mmHg, or by at least 20 % of the baseline value. HVPG is a useful parameter for selecting patients responsive to pharmacotherapy. However, due to the invasiveness of the method, HVPG measurement has not become part of routine clinical practice. Further investigations of noninvasive methods are therefore warranted.
In a study by Cioni et al. [1] , the usefulness of duplex Doppler sonography for predicting the effect of beta-blocker was investigated. In 30 patients with cirrhosis of the liver who were at high risk for variceal bleeding, the maximum portal flow velocity, portal blood flow, and congestion index were measured before and four hours after the administration of 40 mg of propranolol. Among a series of clinical, laboratory, and instrument-based parameters, the percentage decrease in maximum portal flow velocity was found to be the only reliable parameter for predicting variceal bleeding. The best cut-off value was 12 %. Patients with a 12 % or more decrease in portal flow velocity had a 25 % prevalence of bleeding, versus 64 % in patients with no decrease in portal flow velocity.
Escorsell et al. [2] compared noninvasive endoscopic measurement of variceal pressure to hepatic venous pressure measurement (HVPG). Fifty-five patients with liver cirrhosis were studied before and after 4 months of continued propranolol therapy. Over a follow-up period of 28 ± 11 months, 16 patients experienced variceal bleeding. Nonbleeders had a significant reduction in endoscopically measured variceal pressure compared to bleeders (-15 % ± 24 % vs. 5 % ± 20 % of the baseline value). Corresponding to the results of HVPG measurements (decrease ≥ 20 % : 6 % bleeding; decrease < 20 % : 45 % bleeding), a reduction of ≥ 20 % in variceal pressure was associated with a bleeding rate of only 5 %, versus 45 % with a pressure decrease < 20 %.
Moitinho et al. [3] investigated the relationship between the increase in portal pressure and the outcome of variceal bleeding. In 65 cirrhotic patients with acute variceal hemorrhage, HVPG was measured early after admission to hospital (20.6 ± 15.6 hours). Twenty-three patients had a poor course (failure to control bleeding or early variceal rebleeding), and 42 had an uneventful course. The only variable that was associated with the outcome in patients was HVPG. HVPG was 23.7 ± 6.1 mmHg in patients who had a poor course, and 19.2 ± 3.3 mmHg in patients who had uneventful one (P < 0.0004). An initial HVPG of ≤ 20 mmHg was associated with a significantly longer intensive-care unit stay (7 ± 5 vs. 4 ± 2 days; P < 0.02), longer hospital stay (19 ± 10 vs. 14 ± 6 days; P < 0.002), greater transfusion requirements (9.0 ± 7.7 vs. 4.7 ± 3.2 units) and a worse actuarial probability of survival (one-year mortality, 64 % vs. 20 %; P < 0.002).
Pharmacological Therapy

Beta-Blocker Therapy
Treatment with beta-blockers is widely accepted as the first-choice therapy in primary prophylaxis against variceal bleeding. However, it has been shown that propranolol decreases HVPG to < 12 mmHg or 20 % of the baseline value only in less than one-third of patients. Combination of different drugs, and the use of other nonselective beta-blockers, are therefore still of interest in clinical investigations.
Banares et al. [4] investigated the effect of carvedilol, a nonselective beta-blocker with anti-alpha 1 -adrenergic activity. Thirty-five cirrhotic patients were randomly assigned to receive either carvedilol (n = 14), propranolol (n = 14) or placebo (n = 7). Hemodynamic measurements, including HVPG, were made before and one hour after the medication. Carvedilol caused a significantly greater reduction in HVPG than propranolol. Moreover, carvedilol decreased HVPG to less than 20 % of the baseline value or to ≤ 12 mmHg in a significantly greater proportion than propranolol (64 % vs. 14 %). Both drugs caused similar reductions in hepatic and azygos blood flow, suggesting that the greater HVPG decrease achieved by carvedilol was due to reduced hepatic and portocollateral resistance. Compared to propranolol, carvedilol had a greater systemic vasodilatory effect, leading to arterial hypotension. Further clinical investigations are therefore required before it can be recommended for long-term administration.
Merkel et al. [5] reported the long-term results of combination therapy with nadolol (40 -160 mg/day) and isosorbide mononitrate (10 -20 mg t. i. d.). Over a follow-up period of up to seven years (median 55 months), the combination therapy showed a significantly better effect than the monotherapy. The cumulative risk of bleeding with the two drugs was 29 % and 12 %, respectively. There were few side effects, and no deleterious effects on the occurrence of ascites or on survival occurred with long-term use of this combination.
Vasoactive Drugs
Vasoactive drugs such as vasopressin, somatostatin, and octreotide are known for their ability to reduce portal blood flow due to a splanchnic vasoconstrictive effect. The role of these drugs in the management of acute variceal bleeding has yet to be established. Several studies comparing combined pharmacotherapy and sclerotherapy with either pharmacotherapy or sclerotherapy alone have been recently published.
Villanueva et al. [6] compared somatostatin, administered as a continuous infusion (250 µg/h), with somatostatin infusion plus endoscopic variceal sclerotherapy (EVS) in patients with acute esophageal variceal bleeding. Fifty episodes of esophageal variceal bleeding were randomly allocated to treatment with somatostatin alone, and 50 episodes to receive somatostatin plus EVS using 5 % ethanolamine oleate. In both groups, somatostatin infusion was continued for five days. Failure to control acute bleeding occurred in 24 % of the somatostatin group and 8 % in the combined-therapy group (P = 0.03), and early rebleeding was seen in 24 % vs. 7 %, respectively (P = 0.03).
In another study by Zuberi et al. [7] , endoscopic variceal sclerotherapy (EVS) using ethanolamine oleate was compared to EVS combined with octreotide infusion (50 µg/h continuously for five days). Seventy patients with low-risk cirrhosis who were suffering from acute variceal hemorrhage were included in the randomized study. The hemostasis rate was 85.7 % in the EVS group and 94.3 % in the combined-therapy group (P = 0.24). The early rebleeding rate and blood transfusion requirements were significantly lower, and the hospital stay was significantly shorter in the patients who additionally received octreotide.
A multicenter randomized controlled trial was conducted by Escorsell et al. [8] to compare terlipressin versus sclerotherapy in the treatment of acute variceal bleeding. A total of 219 cirrhotic patients were randomly assigned to receive either repeated intravenous injections of terlipressin (n = 105) (2 mg/4 h until control of bleeding was achieved, followed by infusion of 1 mg/4 h for six days) or emergency sclerotherapy (n = 114) with 5 % ethanolamine oleate or 1 % polidocanol. There were no significant differences in terms of failure rate, early rebleeding, blood transfusion, hospital stay, or six-week mortality.
In a randomized trial, Sivri et al. [9] compared octreotide (50 µg i. v. bolus followed by infusion of 50 µg/h for 12 hours) with endoscopic sclerotherapy using 1 % polidocanol. A total of 52 patients with 66 episodes of bleeding were recruited into the study. Bleeding was initially controlled within six hours in 75 % of episodes by sclerotherapy and in 73.3 % by octreotide infusion (P > 0.05). There were no significant differences between the two groups in terms of early rebleeding, blood transfusion, or hospital mortality.
In a multicenter randomized study [10] , the efficacy of octreotide and EVS in the treatment of acute variceal bleeding was compared. Thirty-seven patients received EVS and 39 received an octreotide infusion of 50 µg/h for 48 hours after a bolus of 100 µg, followed by subcutaneous injection of 100 µg/8 h for an additional 72 hours. Initial hemostasis was achieved by EVS in 94.6 % and by octreotide in 84.6 % (not significant). The treatment failure, rebleeding, and mortality rates were similar in the two groups ( Table 1) .
A single-center, double-blind, placebo-controlled trial was conducted by Junquera et al. [11] to compare the effectiveness of somatostatin infusion alone to that of somatostatin plus oral isosorbide 5-mononitrate. Sixty patients with bleeding from esophageal or gastric varices were randomly assigned to receive a somatostatin infusion (250 µg/h) plus oral isosorbide 5-mononitrate (40 mg/12 h) (group I) or somatostatin plus a placebo (group II) for 72 hours. Bleeding was controlled in 18 of the 30 patients (60 %) in group I and in 26 of the 30 patients (87 %) in group II (P < 0.05). Transfusion requirements and mortality were similar in the two groups, but occurrence of ascites was higher in group I (30 %) than in group II (7 %) (P < 0.05). The authors concluded that in cirrhotic patients with acute bleeding from esophageal or gastric varices, addition of isosorbide 5-mononitrate does not improve the results and induces more adverse effects, and should therefore not be used.
The effectiveness of isosorbide mononitrate in addition to propranolol in the prevention of variceal rebleeding was investigated by Gournay et al. [12] . Ninety-five cirrhotic patients were randomly assigned to receive propranolol alone (n = 49) or propranolol plus isosorbide mononitrate (n = 46). The results suggest that the addition of isosorbide mononitrate improves the effectiveness of propranolol in the prevention of variceal rebleeding (39.1 % vs. 57.1 % rebleeding over two years). However, no significant differences were found in the rebleeding index and survival rate.
Comment
In the primary prevention of variceal bleeding, beta-blockers remain the first-line treatment as long as the efficacy of endoscopic variceal ligation (EVL) has not yet been proved Patients in the EVS group had a significantly lower rebleeding rate (P < 0.05) and survived significantly longer (P < 0.001). During the five-year follow-up period, all patients in the non-EVS group died, 16 of them (40 %) from gastrointestinal bleeding, including esophageal variceal bleeding. Nine patients (20.9 %) in the EVS group had rebleeding, and five (11.6 %) died. In both groups, the major cause of death other than bleeding was hepatic failure. The influence of the severity of cirrhosis and of hepatocellular carcinoma on the efficacy of EVS was also analyzed in this study. Interestingly, the authors were able to show that EVS prolonged survival in patients with either Child's A or B grade hepatic function (P < 0.001), but not in those with Child's C hepatic function. EVS was only effective in prolonging survival of patients with hepatocellular carcinomas that were smaller than 5 cm (P < 0.001) and of the nodular type (P < 0.001). EVS was not effective in patients with portal vein thrombosis (P < 0.01).
The completeness of eradication is decisive for the outcome. A study by Matsumoto et al. [14] investigated the long-term survival in cirrhotic patients with complete and incomplete eradication of esophageal varices. Forty patients were treated using EVS for acute variceal bleeding. In 28 patients, the procedure was repeated at seven-day intervals until the varices had been completely eradicated (complete eradication group, CEG). Twelve patients did not achieve complete eradication because their hospital stay was limited for personnel reasons (incomplete eradication group, IEG). The number of sessions in the CEG was 4.2 ± 2.6, compared with 2.2 ± 1.8 in the IEG. The total amounts of sclerosant used in the two groups were 49.6 ± 27.2 ml and 26.0 ± 22.1 ml 5 % ethanolamine oleate, respectively. To evaluate variceal recurrence, endoscopy was carried out one month after treatment and every three months thereafter. The recurrence and rebleeding rates were significantly higher in the IEG group compared to the CEG one (100 % vs. 0 %, 58.3 % vs. 0 %, respectively, P < 0.01). The cumulative five-year survival rate was significantly higher in the CEG group compared to the IEG group (68.2 % vs. 43.2 %, P < 0.05). The authors concluded that complete eradication by EVS is effective both in preventing rebleeding and in improving the survival in cirrhotic patients.
The techniques of sclerotherapy and sclerosants that are in use have not yet been standardized. Sclerosants are injected either intravariceally or paravariceally. In Europe and Japan, 5 % ethanolamine oleate or 1 % polidocanol are used, while in the USA, sodium morrhuate and sodium tetradecyl sulfate are preferred.
In the study by Meirelles-Santos et al. [15] , the effectiveness and safety of absolute ethanol was compared to that of 5 % ethanolamine oleate. A total of 157 patients with portal hypertension and a history of variceal bleeding were randomly assigned to receive sclerotherapy with absolute ethanol (n = 66) or 5 % ethanolamine oleate (n = 91). Sclerotherapy with absolute ethanol was as effective as with 5 % ethanolamine oleate (eradication rate: 91 % vs. 88.7 %), with comparable complication rates and numbers of sessions.
In an experimental study by Nishida et al. [16] , the sclerosant Xiao Zhi Ling (XZL), which consists of Chinese nutgalls and aluminum potassium sulfate, was compared to 5 % ethanolamine oleate and 1 % polidocanol. The authors were able to show that XZL caused more severe damage at the injected site of the varices than the two other sclerosants. XZL should therefore be used to treat esophageal varices by paravariceal injection in smaller amounts than the two other sclerosants.
In a randomized controlled trial, Goncalves et al. [17] investigated the efficacy of prophylactic EVS in 100 children. Children who had portal hypertension with esophageal varices of less than grade IV with no previous variceal or intestinal bleeding were randomly included in the study. Fifty children received EVS, and 50 children received no treatment. Most of the children had Child's A hepatic function -46 in the EVS group (92 %) and 42 in the con-trol group (84 %). After a median follow-up of 4.5 years, 47 children in the EVS group (94 %) had no esophageal bleeding, compared to 29 children in the control group (58 %). Interestingly, eight children in the EVS group (16 %) developed hypertensive gastropathy, compared to three in the control group (6 %; P < 0.05). EVS did not affect the survival rate.
EVS is an effective method in the treatment of esophageal varices, with excellent results in variceal eradication. The main disadvantage of EVS remains the high morbidity of the procedure due to deep ulceration, which may lead to rebleeding, stricture, and perforation. The complication rates vary in different studies and are operator-dependent.
Ligation
In the elective treatment of esophageal varices, EVL has now been clearly proved superior to EVS, particularly with regard to procedure-related morbidity. Esophageal varices can be eradicated in an average of three sessions of EVL. However, the long-term results with EVL are less encouraging, due to early variceal recurrence. Understandably, therefore, most of the papers published in 1999 -2000 dealt with attempts to improve the results of EVL.
Efforts have been made to improve the ligation technique, and the use of the multiple-band ligator has made ligation easier. Several authors investigated the use of endoloops in variceal bleeding and compared them to EVL. Hepworth et al. [18] compared the efficacy of endoloop hemostasis with injection and band ligation in an experimental model. The objection to band ligation raised by the authors is that preloaded bands may lose some of their elasticity with time.
The authors used an end cap and a right-angled endoloop that allows suctioning of the varix into the cap before deploying the loop. Endoloops appear to be more effective because they exert more compressive force on tissue than band ligation. The disadvantage of endoloops that was noted in this experimental study is that when multiple loops are deployed, an endoloop has to be loaded onto the delivery system and passed through the channel of the endoscope each time, whereas the release of rubber bands using a multiple ligator is faster. In addition, the endoloop delivery system may interfere with the suction of blood and secretions. The risk of tearing the varix seems to be higher with endoloops than with rubber band.
Shim et al. [19] studied the effect of mini-detachable snare ligation (MDSL) in the treatment of esophageal varices in 103 patients. Obvious advantages of MDSL are the ability to place multiple snares and the possibility of using other endoscopic accessories after snare ligation without needing to withdraw and reintroduce the endoscope. Forty-six patients were assigned to receive MDSL, while 57 underwent multiple-band ligation. Hemostasis was achieved in 86 % and 85 %, respectively; recurrent bleeding occurred in 5.5 % and 5.3 %, respectively, and the variceal recurrence rate was 11 % in both groups. No serious complications occurred in either group. The follow-up periods varied widely -six months in the MDSL group to 16 months in the EVL group. The authors criticized the high cost of multipleband ligation and the reduction in the field of vision caused by the loaded bands covering the transparent hood.
Ell et al. [20] have developed the first reusable multipleband ligator (Euroligator system). The system has been used 22 times for ligation of esophageal varices -in 16 patients as an elective procedure, and in six patients as an emergency procedure. No technical problems have been encountered. The Euroligator system operates on a different principle from that of the other multiple-band ligators available. Rotation of the driver, which is locked onto the endoscope via a Luer-lock connection, pulls back the inner cylinder by rotating the flexible shaft. This in turn causes shedding of the rings mounted on the inner cylinder. To maintain maximum tension, the rings are mounted on the head of the multiple ligator immediately before they are to be used. No spontaneous shedding of the rings was observed after successful ligation. The authors attribute this to the fact that the rings are only mounted on the multiple ligator head immediately before use, and are therefore at maximum tension.
In a study by Lo et al. [21] on the prevention of rebleeding, EVL was compared with a combination of EVL, betablocker, and sucralfate (triple therapy) in 122 patients with esophageal varices. Sixty-two patients were randomly assigned to receive EVL alone, and 60 patients to receive triple therapy. After a median follow-up of 21 months, variceal obliteration was achieved in 43 patients (70 %) in the EVL group and 45 patients (75 %) in the combination group. There were no statistically significant differences between the groups. Rebleeding from esophagogastric varices occurred in 18 patients (30 %) in the EVL group and in seven patients in the combination group (11.6 %; P < 0.05).
Variceal recurrence occurred in 21 of the 43 patients in the EVL group (50 %) and in 12 of the 45 patients in the combination group (26 %; P < 0.05). The authors suggest that a combination of EVL with beta-blocker and sucralfate treatment is more effective in terms of variceal rebleeding and variceal recurrence than EVL alone.
EVL versus EVS
In the randomized study by Hou et al. [22] , with a followup of 55.3 ± 12.5 months, EVL showed lower rebleeding rates than EVS only within the first four weeks of endoscopic treatment. After variceal eradication, there was no difference in the rebleeding risk between EVL and EVS. The overall rebleeding rate was 24 % for EVL and 38 % for EVS. Fifty-one percent of the rebleeding episodes occurred within six weeks of the endoscopic treatment. Fifty percent of esophageal variceal rebleeding episodes were due to EVL-induced ulcers, and in the EVS group the rate was 41 %. The mean number of sessions needed to achieve eradication was 3.7 ± 1.7 in the EVL group, and 5.1 ± 2.2 in the EVS group (P < 0.001). The eradication rates were Similar results were found in an Italian multicenter randomized trial conducted by Masci et al. [23] . A total of 100 patients (50 EVL, 50 EVS) were enrolled. Variceal eradication was achieved in 88 % in the EVL group and 82 % in the EVS group, with a mean of 3.41 and 5.29 sessions of treatment (P < 0.001), respectively. Stenosis occurred in one patient treated with EVL and in nine patients treated with EVS. During eradication, rebleeding occurred in 12 % in the EVL group and 42 % in the EVS group (P < 0.001). In contrast to the study by Hou et al. [21] , rebleeding episodes after eradication were fewer with EVS than EVL (8 % vs. 14 %; not significant).
Esophageal varices tend to recur more often after EVL than after EVS. In a randomized trial conducted by de la Peña et al. [24] in which EVL was compared to EVS, the variceal recurrence rate at one year was 47 % vs. 23 % and 92 % vs. 55 % at three years. In terms of the number of treatment sessions and the rebleeding and complication rates, EVL was otherwise better than EVS (all differences were statistically significant).
EVL plus EVS versus EVL
Another way of improving the results of endoscopic treatment is to combine the advantages of EVL and EVS. Four randomized trials have compared EVL alone with EVL plus EVS. In the study by Djurdjevic et al. [25] , in which low-volume sclerotherapy (1 ml polidocanol 1 %) was injected into varices proximal to each ligation, no significant differences were found with regard to the number of sessions needed for eradication (2.3 ± 0.7 vs. 2.4 ± 0.7) or the recurrent bleeding rate (14 % vs. 20 %).
Al Traif et al. [26] conducted a similar trial comparing EVL alone with combination therapy, in which 1 -2 ml 1 % polidocanol was injected intravariceally proximal to the ligation sites. The authors found no significant differences between the two treatment methods in terms of hemostasis (86 % vs. 100 %), blood transfusion units needed (2 ± 0.6 vs. 3 ± 0.8), number of sessions required to eradicate varices (3.6 ± 0.4 vs. 3.8 ± 0.5), treatment failure (14 % vs. 17 %), stricture rate (0 % vs. 3 %), variceal recurrence rate (6 % vs. 21 %), rebleeding rate (23 % vs. 17 %), or mortality rate (23 % vs. 10 %).
In a randomized, prospective and controlled trial, Argonz et al. [27] compared EVL to EVL plus EVS in the prevention of recurrent variceal bleeding in cirrhotic patients. Forty-one patients received EVL alone, and 39 patients had EVL plus EVS. Polidocanol 1 % was simultaneously In contrast to the above three studies, Umehara et al. [28] performed intravariceal sclerotherapy with 5 % ethanolamine oleate 2 -3 cm proximal to the gastroesophageal junction. Using a proximal balloon tamponade attached to the endoscope, the sclerosant (mixed with contrast medium) was injected under fluoroscopic monitoring until the feeding veins were filled. EVL was carried out subsequently in the same session. In the following sessions, EVS was performed paravariceally using 1 % polidocanol to treat the remaining varices. Using this technique, the one-year and three-year cumulative variceal recurrence rates were significantly lower in the scleroligation group than in the group treated with EVL alone (9.5 % and 22.1 % vs. 61.9 % and 72.2 %, respectively). The survival rates and procedurerelated complication rates were similar in the two groups.
Comment
The published results with combination therapy using EVL and EVS have been conflicting. Dhiman and Chawla [29] suggest that the different outcomes of these trials may be related to the different sclerotherapy techniques used. They emphasize the important role of feeding veins (perforating veins and paraesophageal collaterals) in the formation of recurrent varices. Umehara et al. [28] probably obliterated the feeding veins using their vigorous approach. This hypothesis needs to be proved. High-resolution EUS may be useful to confirm obliteration of the feeding collaterals, corresponding to permanent variceal eradication.
Apart from all these clinical investigations, it is a fact in everyday practice that EVL is associated with a relatively high rate of variceal recurrence. This shortcoming requires regular surveillance and repeat treatment if necessary. Sclerotherapy will continue to play a role in patients with small varices that are unsuitable for band ligation. Patients with large recurrent varices that are refractory to EVL treatment may be considered as candidates for obliteration using cyanoacrylate adhesive.
Prophylactic Endoscopic Treatment
In addition to beta-blocker therapy, EVL is increasingly being used for primary prophylaxis against variceal bleeding, although this is not yet generally accepted. Unlike sclerotherapy, EVL is associated with fewer complications. This is the main reason why several investigators have attempted to confirm the efficacy of EVL in the primary prevention of variceal bleeding. Several prospective trials have demonstrated that prophylactic EVL at least reduced the risk of bleeding in comparison with a control group [30 -32] . In the first study comparing prophylactic EVL and the beta-blocker propanolol in patients with high-risk esophageal varices, EVL was found to be more effective and safer than propranolol in terms of reducing the risk of first variceal hemorrhage (15 % vs. 43 %; P = 0.04) [33] .
Masumoto et al. [34] compared prophylactic EVL alone (18 patients) with EVS alone (20 patients) or EVL combined with low-dose EVS (21 patients). During a followup of 24 months, no variceal rebleeding occurred in any of the three groups. The variceal recurrence rates were 40 % in the EVL group, 10 % in the EVS group, and 12 % in the combination group, and the complication rates were 5 %, 50 %, and 10 %, respectively. The authors concluded that combination therapy is the most effective prophylactic treatment ( Table 2) .
Matsumoto et al. [35] investigated the relationship between left gastric vein hemodynamics and variceal recurrence in patients undergoing prophylactic EVL for high-risk esophageal varices. The authors concluded that prophylactic EVL appears to be useful in patients with hepatopetal flow in the gastric vein and with hepatofugal flow with an extraesophageal shunt.
Comment
Due to the conflicting results with prophylactic EVL, larger trials are warranted to test whether prophylactic EVL or even combined EVL and low-volume EVS may be superior. Beta-blocker treatment should be regarded as the first-line therapy. The prevention of first variceal bleeding is undoubtedly one of the major challenges in the treatment of portal hypertension.
Gastric Varices
Gastric varices have a high risk of rebleeding after EVS and EVL. This is particularly true of huge fundic varices with extensive tributaries. EVS and EVL only affect part of these large varices, and do not cause thrombosis of the entire varix. Necrosis caused by sclerotherapy or ligation may induce massive bleeding from the still open varices, resulting in a high mortality rate. In order to improve the results, Yoshida et al. [36] combined detachable snare treatment, band ligation, and sclerotherapy in treating fundic varices. The main varices were ligated with the detachable snare. The surrounding smaller varices were first sclerosed with 5 % ethanolamine oleate and then ligated with rubber bands. Thirty-five patients were treated in this way -eight on an emergency basis, six on an elective basis, and 21 for primary prophylaxis. Hemostasis was achieved in all eight patients with acute bleeding, and variceal obliteration in 97 %. The two-year cumulative recurrence rate was 15 %, and the rebleeding rate was 8 %. Despite these excellent results, the authors noted that obliteration therapy with cyanoacrylate is more effective in the treatment of fundic varices. They suggest that this combination therapy should be used in their country, as cyanoacrylate is not available there.
Use of Cyanoacrylate in Gastric Varices
For more than 15 years, the tissue glue N-butyl-2-cyanoacrylate has been successfully used in Europe and many other countries except the USA. In Europe, the substance has recently been approved for the treatment of esophageal and gastric varices under the proprietary name Glubran™ (GEM, Viareggio, Italy). Cyanoacrylate is injected intravascularly to obliterate varices. Cyanoacrylate is highly effective for controlling massive bleeding from esophagogastric varices (e. g., bleeding from EVL-induced ulcers) and obliterating large fundic varices (Figure 1) .
Kind et al. [37] reported 12 years' experience with the use of cyanoacrylate in a total of 174 patients suffering from bleeding gastric varices. The hemostasis rate was 97.1 %, with an early rebleeding rate of 15.5 % and a hospital mortality rate of 19.5 %. Complications, including chest pain and treatment-related ulcer-induced bleeding, occurred in 2.9 %. The results were as good as those of EVS for esophageal variceal bleeding, but the treatment-related morbidity Huang et al. [38] reported their six-year experience of using cyanoacrylate injection to treat bleeding gastric varices. A total of 90 patients with active or recent gastric variceal bleeding were treated endoscopically with Histoacryl™ mixed with Lipiodol™ at a ratio of 1 : 1. In 94.4 % of the cases, the gastric varices were located at the fundus and posterior wall of the most proximal body of the stomach. Hemostasis was achieved in 94. In a historical comparative study conducted by Lee et al. [39] , 101 patients presenting with bleeding gastric varices were treated with a bolus injection of cyanoacrylate (0.5 ml Histoacryl™ mixed with 0.7 ml Lipiodol™). Forty-seven patients received "on-demand" repeat injection only in response to recurrent bleeding, and 54 patients underwent twice-weekly EUS followed by repeated injection of cyanoacrylate (repeated-injection group) until all gastric varices were obliterated. The rate of early rebleeding (≤ 48 hours) was 7.4 % in the repeated-injection group and 12.8 % in the on-demand group. The difference was not statistically significant. However, the late rebleeding rate was significantly lower in the repeated-injection group (18.5 % vs. 44.7 %). The cumulative probability of a rebleeding-free interval was higher, and there was also a numerical trend toward improved survival, in the repeatedinjection group.
In a retrospective study, Battaglia et al. [40] reported their experience using cyanoacrylate in 68 patients with gastric varices due to cirrhosis of the liver. Thirty-two patients were treated for acute variceal bleeding, 29 electively, and seven prophylactically. The initial hemostasis rate was 96.8 %, and early rebleeding occurred in 11 patients (34.4 %). However, actual rebleeding from gastric varices was only observed in five patients (15.6 %). Of the 36 patients treated electively or prophylactically, two (5.6 %) had rebleeding from gastric varices. To achieve complete variceal eradication, an average of 1.3 sessions with a mean amount of 4.9 ml cyanoacrylate was required. After a mean follow-up of 45.4 months, gastric varices recurred in 13 patients (30.9 %). Late rebleeding occurred in 15 patients, but only four of them bled from gastric varices. Nineteen patients died during the follow-up period, one of them from gastric variceal bleeding. The overall survival rate at five years was 58 % ( Table 3) .
Risks of Cyanoacrylate Injection
In contrast to the widespread use of cyanoacrylate injection, the number of complications reported in the literature appears to be relatively small. Undoubtedly, the most serious side-effect of intravariceal injection of cyanoacrylate is embolization. There have been some case reports of embolization of the adhesive into the lung, spleen, or brain. Over a period of six years, Huang et al. [38] did not ob- In a series of 68 patients with gastric varices, Battaglia et al. [40] reported a total of five cases of asymptomatic microembolization in the lung and pelvic region. More recently, the same group described two cases of visceral fistula [41] . In the first case, a fistula occurred between the stomach and pleural cavity six months after repeated cyanoacrylate injections for recurrent bleeding from gastric varices. In the second case, an esophageal fistula occurred seven days after a cyanoacrylate injection to control bleeding that was refractory to sclerotherapy.
Due to the fear of embolization, some investigators are injecting undiluted cyanoacrylate. However, the disadvantage of using undiluted adhesive is that the needle may easily become stuck. Bhasin et al. [42] reported two cases in which the needle remained stuck in the varix. In both cases, it was possible to remove the needle along with some solidified cyanoacrylate using biopsy forceps or a snare, without causing significant bleeding.
Kulling et al. [43] evaluated the efficacy of poly-N-acetylglucosamine (P-GlcNAc) in an animal study. This substance, isolated from marine microalgae, is a polysaccharide polymer that quickly stops hemorrhage by stimulating erythrocyte aggregation when applied externally to bleeding wounds. Viscous P-GlcNAc (2.5 -3.5 %) was injected intravariceally and paravariceally in eight heparinized dogs with bleeding esophageal varices. In all cases, the variceal bleeding was stopped by the formation of a cast in the varix, similar to the effect of cyanoacrylate. No rebleeding, ulceration, or stricture occurred. No evidence of embolization was observed in this study, but the authors do not completely exclude the possibility of embolism, especially if larger amounts of gel are necessary to treat larger varices. More interestingly, P-GlcNAc gel was replaced by connective tissue within 90 days, causing permanent obliteration of the vessel. The results of this animal study suggest that P-GlcNAc gel may be safer than cyanoacrylate. Further clinical studies are needed to show whether these results achieved in dogs can be reproduced in humans.
Comment
Cyanoacrylate is used to obliterate large and massively bleeding varices. Injections therefore have to be made strictly into the varices. Owing to instantaneous polymerization of the cyanoacrylate on contact with blood and its adhesive properties, the solidified adhesive usually remains as a cast in the vessel. Embolization can presumably occur if an excess amount is used per injection, or if the adhesive is overdiluted with Lipiodol™. We recommend diluting cyanoacrylate with Lipiodol™ at a ratio of 0.5 : 0.8. Three to four days after the injection, necrosis occurs on the variceal wall, and the cast is slowly extruded. The extrusion process may last several weeks and sometimes even months. The results of the study by Lee et al. [39] demonstrated that the rebleeding rate declines, with repeated injections achieving complete variceal obliteration. Ideally, variceal obliteration should be accomplished at the initial procedure itself in a single session. Obliterated varices become firm, and can be easily confirmed by palpation with the injection catheter. However, there is some cause for concern that injection of an excess amount of cyanoacrylate may be associated with a high risk of embolization.
To prevent such complications, the individual dosage of cyanoacrylate per injection should be strictly limited to a maximum of 1 ml for fundic varices. If larger amounts are needed due to the large size of the varices, injections should be performed sequentially.
Endoscopic Ultrasonography
Endoscopic ultrasonography (EUS) is attracting increasing interest in the management of esophageal varices. EUS is able to elucidate the pathophysiology of portal hypertension and assess the efficacy of variceal treatment. In addition, EUS can be used to assist injection sclerotherapy in an attempt to improve the results. In contrast to the initially disappointing results with EUS, several recent studies using high-resolution EUS and color Doppler EUS have demonstrated a correlation between large paraesophageal or periesophageal collateral veins and variceal recurrence, and rebleeding following endoscopic treatment. This topic, which has been reviewed in previous issues of this journal, remains one of the principal areas of further EUS investigation in the field of portal hypertension. The background for this continuing clinical research is the still relatively high recurrence rates of varices and variceal bleeding after A study by Irisawa et al. [44] investigated the role of periesophageal collateral veins in the formation of esophageal varices. Twenty-two patients with untreated varices were examined using a 20-MHz EUS catheter probe, as well as by endoscopy. Collateral veins were classified into a) periesophageal collateral veins adjacent to the muscularis externa layer of the esophagus and b) paraesophageal collateral veins external to the esophageal wall, but without contact with the muscularis externa. Periesophageal varices are situated in the connective tissue surrounding the esophagus, whereas the paraesophageal collaterals are located in the mediastinum and run longitudinally into the azygos and hemiazygos vein. The authors found that large esophageal varices significantly correlate with the presence of severe periesophageal collateral veins. In contrast, the extent of paraesophageal collaterals does not have any significant influence on the size of the esophageal varices. The prevalence of perforating veins increased with the size of esophageal varices. Perforating veins were found more often in connection with the periesophageal varices than connected to the paraesophageal collateral veins (81.8 % and 27.3 %, respectively). The authors conclude that periesophageal collateral veins play a more important role in the formation of esophageal varices than do paraesophageal collateral veins.
EUS appears to be more accurate than percutaneous transhepatic portography in the assessment of periesophageal and paraesophageal collateral veins. Angiographically, periesophageal veins are barely distinguishable from the esophageal varices, due to the inability to delineate the wall layers. In addition, EUS is less invasive than percutaneous transhepatic portography.
To improve the diagnostic yield of EUS in the evaluation of variceal eradication after EVL, Koutsomanis and Papakonstantinou [45] used fractal-assisted image analysis. In this preliminary study in five consecutive patients, they claimed that the interpretation of EUS findings becomes more objective and hence more precise with the aid of mathematical image analysis.
Apart from the Child's stage of liver disease, the size of varices and the presence of red spots or hematocystic spots are recognized risk factors for bleeding. Red spots or hematocystic spots represent focal weaknesses in the extremely thin variceal wall, and are considered to be precursors of variceal rupture. Schiano et al. [46] studied this endoscopic finding using a 20-MHz ultrasound catheter probe. In six of ten patients with endoscopically diagnosed hematocystic spots, EUS revealed saccular aneurysm-like projections on the variceal surface. The value of this EUS finding in predicting variceal hemorrhage will require further investigation. Comparative studies are needed to determine whether this sonographic feature is more reliable than endoscopic signs of red spots.
Chung et al. [47] measured variceal volume using a 20-MHz catheter probe in five patients with esophageal varices. The results confirmed their prior in vitro findings suggesting that high-resolution EUS is an accurate and reproducible method of measuring variceal volume. Ongoing clinical studies are expected to determine the suitability of this method for predicting variceal bleeding and monitoring the efficacy of pharmacological therapy.
In the study by Lee et al. [48] , color Doppler EUS was used to assess azygos blood flow in patients with portal hypertension. Azygos blood flow was found to correlate with the Child-Pugh grade of cirrhosis, and it responded to bolus injections of terlipressin and somatostatin. The authors concluded that color Doppler EUS is useful for assessing azygos blood flow in portal hypertension and for monitoring the effects of vasoactive agents.
The same group in Hong Kong reported, more recently, the use of EUS to monitor the results of cyanoacrylate injection in bleeding gastric varices [39] . Fifty-four patients underwent twice-weekly EUS examinations using a radialscanning echo endoscope, followed by repeated injection of cyanoacrylate. In a historical comparison with a series of 47 patients who received repeat cyanoacrylate treatment only on the occasion of recurrent bleeding, patients monitored by EUS who underwent repeat treatment in the same session, depending on the EUS results, have shown a significantly lower rate of recurrent bleeding and a higher cumulative probability of having an interval free of recurrent bleeding. There was also a numerical trend toward improved survival in these patients. The usefulness of EUS for monitoring the results of cyanoacrylate injections in gastric varices is debatable, since the completeness of variceal obliteration can be demonstrated reliably and more simply by catheter palpation. Further studies comparing these two methods for the assessment of the treatment end point, especially in relation to cost-effectiveness, are needed before this approach can be recommended.
EUS-Guided Sclerotherapy
The first report of EUS-guided sclerotherapy was presented by Lahoti et al. [49] . Five patients with esophageal varices (three patients with grade III and two with grade IV esophageal varices) underwent EUS-guided sclerotherapy using a linear-array scanning echo endoscope and a 2.5 mm injection catheter. A total of 2 -4 ml sodium morrhuate per injection site was applied directly at the perforating vessels until the flow was completely impeded. Endoscopy with EUS-guided sclerotherapy was repeated at two-week intervals until EUS documented obliteration of the esophageal varices. A mean of 2.2 sessions (range two to three sessions) was required to achieve complete obliteration. None of the patients had recurrent bleeding, and no deaths occurred during a mean follow-up period of 15 months (range 6 -23 months). One patient developed a stricture, which was successfully managed with balloon dilation. No other complications were reported.
The results of this pilot study are encouraging, and warrant further larger trials in order to confirm the routine practicability of the method and whether the results are reproducible. As a corollary, these results may provide the strongest support yet for the belief that perforating veins play a key role in the development of esophageal varices.
Transjugular Intrahepatic Portosystemic Shunt
One of the major indications for transjugular intrahepatic portosystemic shunt (TIPS) is bleeding esophagogastric varices. Studies comparing the technique with endoscopic modalities recall the period during the 1980's when endoscopic sclerotherapy was being compared with shunt surgery. At that time, several randomized studies demonstrated that shunt surgery was superior to sclerotherapy in terms of preventing rebleeding, but not in improving survival. Higher procedure-related morbidity and mortality were the main reasons for favoring endoscopic treatment.
A similar scenario appears to be repeating itself today. There is no doubt regarding the short-term decompressive effect of TIPS on portal hypertension. In terms of preventing rebleeding, TIPS is more effective than any endoscopic procedure. However, owing to the complications of encephalopathy and stent occlusion, the long-term efficacy of the procedure is questionable. The cost-effectiveness of the procedure is another of the issues involved.
Two meta-analyses were published in 1999, one by a group in Italy and the other by a group in the United Kingdom. The British study [50] analyzed 11 randomized trials involving 811 patients, and the Italian one [51] included 11 randomized trials with 750 patients. Ten of the trials in the two meta-analyses were the same. The British one included the final results of the same German trial comparing TIPS with EVL (published in abstract form), including higher final patient numbers. The median follow-up period ranged from 10 to 32 months in the various trials. Both meta-analyses concluded that TIPS is more effective in preventing variceal rebleeding than EVS (19 % vs. 47 %). A significant superiority for TIPS was shown in all but one study. Interestingly, the British meta-analysis showed that the benefit of TIPS for preventing rebleeding was greater in studies comparing TIPS with EVL (odds ratio 4.52) and with EVS plus propranolol (odds ratio 3.73) than in studies comparing TIPS with EVS alone (odds ratio 2.86). The authors of both meta-analyses concluded that TIPS cannot be recommended as the first-line treatment for prevention of variceal rebleeding, due to the increased risk of post-treatment encephalopathy and the lack of improvement in survival.
TIPS dysfunction, as the main cause of recurrent variceal bleeding, was observed in 55 % of patients [50] . To achieve good results, regular surveillance is therefore mandatory. Doppler ultrasonography appears to be less sensitive than angiography for evaluating stent patency. Routine use of angiography for surveillance would again increase the already high total costs of repeated treatment with TIPS.
Cost-Effectiveness of TIPS
A cost-effectiveness analysis was recently conducted by Russo et al. in the USA [52] . The calculations were based on a decision model similar to the design of clinical trials comparing TIPS with endoscopic treatment plus propranolol. A hypothetical cohort of patients with variceal bleeding would be treated first with EVS, and then subsequently randomized either to TIPS, EVL, or EVS, and followed for one year. Data available from the literature concerning the course and outcome associated with these treatment modalities were used for the cost estimates. Although prices for the procedures in the United States are higher than in many other countries, the results of this cost analysis comparing TIPS, EVS, and EVL can be used to demonstrate the efficacy of TIPS. Owing to its lower rebleeding rate, TIPS is probably more cost-effective during the first year than repeated endoscopic therapy. However, due to the increased rate of stent dysfunction requiring revision, the total costs for TIPS in patients who survive more than one year will be significantly higher. The authors therefore suggest that TIPS should only be used in patients with moderately advanced liver disease who are expected to undergo liver transplantation within a year. However, this idea may be inconsistent with the fact that TIPS is associated with a higher procedure-related morbidity and mortality in such patients [53] .
TIPS for Bleeding Gastric Varices
As a rescue measure, Barange et al. [54] recommend TIPS for recurrent bleeding from gastric varices that have not responded to conservative, endoscopic, or surgical treatment. Ten of 48 patients admitted for bleeding gastric varices were treated successfully with vasoactive medication and/ or Linton balloon tamponade, as well as sclerotherapy or cyanoacrylate injection. Two underwent surgery (portocaval shunting, esophageal transection). Four patients died of massive uncontrolled hemorrhage within a few hours of admission. TIPS was able to achieve hemostasis in 18 of 20 acutely bleeding patients. There were complications in seven of the total of 32 patients treated with TIPS, and four of them (12 %) died (acute liver failure, peritoneal bleeding, sepsis, massive bleeding secondary to portal vein thrombosis). The stent patency rates at one month, six months, and one year were 84 %, 74 %, and 51 %, respectively. For the same follow-up periods, the rebleeding rates were 14 %, 26 %, and 31 %, and the survival rates were 75 %, 62 %, and 59 %. De novo encephalopathy occurred in 16 % of the patients. Patients were followed up until death or transplantation, or for at least one year (median 509 days, range 4 -2230 days). A total of 19 patients (48 %) died within a mean of 290 days (range 4 -1428 days), with variceal bleeding and liver failure being the commonest causes of death. 
TIPS for Ectopic Varices
Bleeding from stomal or rectal varices occurs infrequently. Experience in the treatment of these types of varices is still scanty. Shibata et al. [55] reported their experience in five patients with parastomal varices and seven with anorectal varices who underwent TIPS for hemorrhage that was refractory to conservative management. TIPS was successful in controlling the bleeding. Three patients developed encephalopathy, two died of causes unrelated to the procedure within 30 days of TIPS placement, and four required stent revision within one year of TIPS.
Predictors of Mortality after TIPS
In a retrospective study, Chalasani et al. [53] evaluated factors determining the mortality in patients with advanced cirrhosis of the liver after TIPS. A total of 119 patients who had undergone TIPS for recurrent variceal bleeding (n = 46), refractory ascites (n = 49), and hepatic hydrothorax (n = 24) were studied. Of the 21 variables investigated, acute variceal bleeding requiring emergency TIPS and a serum bilirubin level higher than 3.0 mg/dl were found to be independent predictors of the 30-day mortality. In addition to these two variables, an alanine aminotransferase (ALT) level over 100 IU/l and pre-TIPS encephalopathy were found to be independent determinants of late mortality during a follow-up period of up to three years. Highrisk patients who had all of these factors had a mortality as high as 90 % within a few weeks of TIPS. Sepsis was the most common cause of early death.
Complications of TIPS
Procedure-related complications of TIPS include intrahepatic injury, portal vein thrombosis, bleeding, and infection. De Simone et al. [56] reported a 10 % prevalence of sustained bacteremia after TIPS placement. In all ten patients affected during 99 TIPS procedures, bacteremia resolved with intravenous antibiotics after a median of two weeks of treatment. No sepsis was reported.
Petit et al. [57] reported two cases of iatrogenic dissection of the portal vein during a TIPS procedure. This is a rare complication, but it can have a significant impact on the outcome.
Effects of TIPS on Hepatic and Systemic Hemodynamics
In addition to the short-term hemodynamic effects of TIPS, Lotterer et al. [58] studied the long-term hemodynamic changes in 21 cirrhotic patients up to one year after TIPS. The direct measurements were achieved by catheterization of the pulmonary artery and the azygos vein via the femoral route. Apart from the obvious fall in portal pressure, TIPS was found to significantly increase the cardiac output immediately and during the first year after the procedure. Previous studies have investigated systemic hemodynamics only at one month after TIPS. Patients with pulmonary hypertension and compromised cardiac function are therefore at risk for developing hemodynamic problems not only during the first months, but probably up to one year after TIPS placement.
Comment
For a short while, it seemed that in the secondary prevention of variceal bleeding, TIPS might be able to replace endoscopic treatment. However, according to the two recently published meta-analysis studies, TIPS has not lived up to these expectations due to the high rate of stent occlusion associated with it. Investigations focusing on the stent material used are therefore needed in order to improve stent patency. In clinical practice, therapeutic decisions in the management of recurrent variceal bleeding will continue to depend on the results of endoscopic treatment with regard to definitive hemostasis, long-term bleeding prevention, complications, and outcome.
Balloon-Occluded Retrograde Transvenous Obliteration
Balloon-occluded retrograde transvenous obliteration (B-RTO) is method of treating bleeding fundic varices that is widely used in Japan. The technique, which was initially carried out via the femoral vein, has recently been modified to use a transjugular approach (transjugular retrograde obliteration). An angiographic catheter with a balloon of either 11 or 20 mm in diameter is inserted through the internal jugular vein via the left renal vein into the spontaneous gastrorenal shunt that is found in more than 90 % of patients with gastric varices. With the occluded balloon, approximately 10 ml of 5 % ethanolamine oleate is injected to obliterate the fundic varices. To create variceal thrombosis, the balloon catheter is kept in place for 24 hours. Chikamori et al. [59] reported successful use of transjugular retrograde obliteration in six patients suffering from bleeding fundic varices. No serious complications and no recurrent bleeding occurred during a follow-up of 6 -66 months. Acute bleeding was initially controlled by cyanoacrylate injection (four patients), EVL (one patient), or surgery (one patient). The authors claim that this technique is an effective and safe method of preventing further bleeding from fundic varices.
